论文部分内容阅读
环胞霉素A(CsA)是新的免疫抑制药物,无论在动物实验还是临床器官移植中,都显示了其控制移植物排斥反应强有力的作用。它的问世标志着器官移植免疫抑制治疗中的一个飞跃。但当它初次应用于临床肾移植时,就表现出了限制其临床应用的主要并发症——肾毒性。近年来国内外对此作了大量的研究,现综述如下。一、CsA肾毒性的发生机理临床上肾毒性似乎是可逆的,随着药物剂量的减低,肾功能改善。人们曾希望长期应用也不会产生严重的肾功能损害。但1984年斯坦福心脏移植小组报道了他们用CsA治疗一年以上的心移植病
Cyclosporine A (CsA) is a new immunosuppressive drug that has shown its potent role in controlling graft rejection in both animal and clinical organ transplantation. Its emergence marks a quantum leap in immunosuppressive therapy for organ transplantation. But when it was first applied to clinical kidney transplants, it showed the main complication of limiting its clinical application - nephrotoxicity. In recent years, a great deal of research has been done at home and abroad. First, the mechanism of CsA nephrotoxicity Clinical nephrotoxicity seems to be reversible, with the reduction of drug doses, renal function improved. People have hoped long-term application will not have serious renal damage. However, in 1984, the Stanford heart transplant team reported that they had been treated with CsA for more than one year